Showing 1 to 5 of 5 results
Cancer Treatment Breakthroughs Extend Patient Survival
Several breakthroughs in cancer treatment were announced, including new immunotherapies significantly increasing survival rates for head and neck, melanoma, and gastric cancers; Car T-cell therapy showing 40% longer survival in advanced gastric cancer; liquid biopsies enabling faster, personalized t...
Cancer Treatment Breakthroughs Extend Patient Survival
Several breakthroughs in cancer treatment were announced, including new immunotherapies significantly increasing survival rates for head and neck, melanoma, and gastric cancers; Car T-cell therapy showing 40% longer survival in advanced gastric cancer; liquid biopsies enabling faster, personalized t...
Progress
28% Bias Score
CAR T-Cell Therapy for NHL: Addressing Access Barriers and System Readiness in Europe
Non-Hodgkin lymphoma (NHL) constitutes a major health challenge in Europe, with annual productivity losses estimated at €110.7 million; CAR T-cell therapy offers a promising but resource-intensive treatment option that requires policy changes for equitable access.
CAR T-Cell Therapy for NHL: Addressing Access Barriers and System Readiness in Europe
Non-Hodgkin lymphoma (NHL) constitutes a major health challenge in Europe, with annual productivity losses estimated at €110.7 million; CAR T-cell therapy offers a promising but resource-intensive treatment option that requires policy changes for equitable access.
Progress
48% Bias Score
CAR T-Cell Therapy Shows Promise for Autoimmune Disease Cure
UK scientists are trialing CAR T-cell therapy—a cancer treatment—to cure autoimmune disorders like lupus, with early results showing potential for remission and prevention, although long-term effects are still unknown.
CAR T-Cell Therapy Shows Promise for Autoimmune Disease Cure
UK scientists are trialing CAR T-cell therapy—a cancer treatment—to cure autoimmune disorders like lupus, with early results showing potential for remission and prevention, although long-term effects are still unknown.
Progress
56% Bias Score
Car T-cell Immunotherapy Extends Life of Gastric Cancer Patients by 40%
A world-first clinical trial in China shows that Car T-cell immunotherapy significantly increases the lifespan of patients with advanced gastric or gastro-oesophageal junction cancer by approximately 40%, offering a potential paradigm shift in the treatment of solid tumors, according to results publ...
Car T-cell Immunotherapy Extends Life of Gastric Cancer Patients by 40%
A world-first clinical trial in China shows that Car T-cell immunotherapy significantly increases the lifespan of patients with advanced gastric or gastro-oesophageal junction cancer by approximately 40%, offering a potential paradigm shift in the treatment of solid tumors, according to results publ...
Progress
48% Bias Score
18-Year Remission Achieved in Neuroblastoma Patient via CAR T-cell Therapy
An 18-year remission in a neuroblastoma patient treated with CAR T-cell therapy, a pioneering immunotherapy involving genetically modified T-cells, showcases its potential for long-term remission in solid tumors, particularly for childhood cancers.
18-Year Remission Achieved in Neuroblastoma Patient via CAR T-cell Therapy
An 18-year remission in a neuroblastoma patient treated with CAR T-cell therapy, a pioneering immunotherapy involving genetically modified T-cells, showcases its potential for long-term remission in solid tumors, particularly for childhood cancers.
Progress
40% Bias Score
Showing 1 to 5 of 5 results